Bloodstream Infection Testing Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents & Consumables), By Sample Type (Blood Culture), By Technology (PCR, ISH), By End-user, By Region, And Segment Forecasts, 2023 - 2030

Bloodstream Infection Testing Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents & Consumables), By Sample Type (Blood Culture), By Technology (PCR, ISH), By End-user, By Region, And Segment Forecasts, 2023 - 2030

Bloodstream Infection Testing Market Growth & Trends

The global bloodstream infection testing market size is expected to reach USD 977.57 million by 2030, registering at a CAGR of 4.5%, according to a new study by Grand View Research, Inc The increasing number of infectious diseases globally and the growing awareness and emphasis on infection control are some of the major factors driving the market. For Instance, according to an epidemiologic survey organized by the European Centre for Disease Prevention and Control (ECDC) in April 2022, there was a notable increase in Candida auris cases across the European region. The survey revealed a significant rise in reported cases of C. auris, from 335 cases reported by 8 countries in 2020 to 655 cases reported by 13 countries in 2021. Bloodstream infections accounted for 15.3% of the reported cases in 2021.

In addition, increasing technological advancements and new product launches by key companies in the market, encouraging government initiatives, and increasing awareness about the importance of blood donation are expected to propel market growth. For instance, in April 2020. DNAe, a next-generation sequencing company, has received a "Breakthrough Device" designation from the U.S. Food and Drug Administration (FDA) for its innovative LiDia-SEQ platform and first assay. This designation enables DNAe to develop rapid and cost-effective tests for infectious disease diagnostics, cancer, infection control, and pandemic preparedness and response. The designated assay focuses on infectious diseases, specifically bloodstream infections (BSI) and antimicrobial resistance (AMR), aiming to detect and identify infections associated with sepsis directly from patient specimens. Through the Breakthrough Device program, the FDA will provide ongoing support and collaborative interactions to facilitate the development and launch of DNAe's LiDia-SEQ sequencing system and BSI/AMR test.

The key players in the market, such as F. Hoffmann-La Roche Ltd., bioMérieux SA, BD, etc., are implementing the strategy of merger & acquisition to enhance product capabilities and promote their product offerings. For instance, in May 2021, F. Hoffmann-La Roche Ltd. completed the acquisition of GenMark Diagnostics for USD 1.8 billion. This acquisition would help Roche expand its molecular diagnostics portfolio. Similarly, in December 2021, the company acquired TIB Molbiol Group, which has around 45 CE-IVD-approved assays for hematology testing, inherited genetic testing, diagnosing infectious diseases, and transplant medicine.

Bloodstream Infection Testing Market Report Highlights

• Based on the product, the reagents and consumables segment accounted for the largest revenue share of the market in 2022. The segment is also expected to grow at the fastest rate over the forecast period owing to the easy availability and frequent purchase of screening products for donors and recipients
• Based on sample type, the blood culture segment accounted for the largest revenue share in 2022 and is expected to witness the fastest CAGR over the forecast period
• Based on technology, the PCR segment held the largest revenue share of the market in 2022 and is expected to grow with the fastest CAGR over the forecast period owing to increasing demand for the tests
• Based on end-user, the hospital and diagnostic centers segment accounted for the largest revenue share in 2022
• North America dominated the bloodstream infection testing market and accounted for the largest revenue share in 2022. This is due to the region's Increasing disposable income, highly developed health infrastructure, and favorable reimbursement policies

Please note The report will be delivered in 2-3 business days upon order notification.